Clinical trials: Bladder Tumors
Bladder Cancer
To Detect the Sensitivity of the UroMark Assay
This is a prospective multicentre observational study to assess the sensitivity of the UroMark assay to detect bladder cancer in participants with new or recurrent disease.
- Trial name
- DETECT II (NCT02781428)
- Where
- 19 sites in United Kingdom
- Volunteers
- 1,643 people
- Sponsor
- University College, London
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Bladder Cancer
Treatment of Recurrent Bladder Cancer With Dendritic Cells
Treatment of recurrent bladder cancer with dendritic cells
- Trial name
- NCT04184232
- Testing
- Dendritic cells, Standard treatment according to the Clinical protocols
- Where
- Belarus
- Volunteers
- 17 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Muscle-invasive Bladder Cancer
Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
The purpose of this study is to assess the efficacy and safety of adding the immunotherapy Avelumab as a fourth component, alongside tumor removal, chemotherapy, and radiation, to increase the chance of preserving the bladder in…
- Trial name
- NCT06686381
- Testing
- Maximum TURBT, Chemotherapy + Immunotherapy Induction, Radiotherapy
- Where
- Lebanon
- Volunteers
- 80 people
- Sponsor
- American University of Beirut Medical Center
Cystoscopic Surgical Procedures, Pain
Physicians' Perception About Patient Pain in Flexible Cystoscopy With Local Anesthesia
Cystoscopy with local anesthesia is commonly performed for the follow-up of bladder cancer, evaluation of hematuria, assessment of urethral strictures, and examination of the lower urinary tract.
- Trial name
- NCT06944314
- Testing
- Diagnostic procedures, Flexible Cystoscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 120 people
- Sponsor
- Marmara University
Bladder Cancer
Cone Beam Computed Tomography (CT) Bladder
This study is designed to investigate whether daily images of the pelvis and bladder using a device called a cone beam CT scanner will help to increase the accuracy of radiotherapy treatment.
- Trial name
- NCT00913536
- Testing
- Using Cone beam CT in patients with Bladder Cancer
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Invasive Bladder Cancer
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)
Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are usually managed by transurethral resection of their bladder tumor (TURBT) alone plus additional intravesical therapy to deliver high local concentrations of a…
- Trial name
- BladderGATE (NCT04134000)
- Testing
- Atezolizumab, BCG
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Fundacion Oncosur
Rectal Cancer
Protocol: Reconstruct the Pelvic Peritoneum Using BPF
Background: Extralevator abdominoperineal excision (ELAPE) may cause various surgical complications including disruption of perineal wound, perineal hernia and adhesive small-bowel obstruction.
- Trial name
- PPRBPF (NCT04177407)
- Testing
- Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
- Where
- China
- Volunteers
- 30 people
- Sponsor
- West China Hospital
Bladder Cancer Stage II
Radiogenomics of Muscle Invasive Bladder Cancer
Patients with suspected bladder tumor will undergo novel 4D MRI imaging along with single cell RNA sequencing in hopes of identifying a radiogenomic signature that can improve our staging of patients with muscle invasive bladder…
- Trial name
- NCT04806334
- Testing
- MRI imaging of the pelvis/bladder, genomic analysis of tumor
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Bladder Cancer
Expression of MCM5 in Urine in Patients With Urothelial Cancers
In patients with non-muscle-invasive bladder cancer, the development and introduction to the clinical practice of an adequately accurate biomarker may allow to limit the indications for performing control cystoscopy.
- Trial name
- NCT03796299
- Testing
- Assessment of expression of MCM5 in the urine (ADX Bladder)
- Where
- Poland
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Bladder Neoplasms
A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)
The purpose of this first-in-human study is to determine the safety and tolerability of SCH 721015 in subjects with transitional cell carcinoma of the bladder.
- Trial name
- NCT00536588
- Testing
- SCH 721015 with SCH 209702
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Breast Cancer
MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
The primary objective is to determine the safety and tolerability of the novel compound, MRx0518 in patients with solid tumours at 30 days post-surgery.
- Conditions
- Melanoma, Breast Cancer, Uterine Cancer, Ovarian Cancer
- Trial name
- MICROBIOME (NCT03934827)
- Testing
- MRx0518 Capsules
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Imperial College London
Transitional Cell Carcinoma of Bladder
PF-03446962 in Relapsed or Refractory Urothelial Cancer
Salvage chemotherapy for advanced urothelial cancer (UC) yields suboptimal response rates of 15-40%, a median progression-free survival of 2-4 months and a median overall survival of 6 months.
- Trial name
- NCT01620970
- Testing
- PF03446962
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Muscle-Invasive Bladder Cancer (MIBC)
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
The purpose of this Phase II, open-label, multicenter, randomized controlled study is to evaluate the efficacy and safety of Enfortumab Vedotin in combination with Toripalimab compared to Gemcitabine plus Cisplatin.
- Trial name
- NCT07647289
- Testing
- enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Peking University Third Hospital
Bladder Cancer
The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial
The study will be a prospective two arms diagnostic phase II single-center trial. Patients referred for diagnosis and treatment with diagnosis of bladder cancer, age > 18 years, ECOG performance status < 2, ability to undergo an…
- Trial name
- FUTURE (NCT07257718)
- Testing
- FAPI PET/CT and liquid biopsy in patients eligible for radical cystectomy, FAPI PET/CT and liquid biopsy in patients eligible for conservative treatment
- Volunteers
- 262 people
- Sponsor
- Chiti Arturo
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Benign Prostate Hyperplasia, Bladder Tumor
Effective Dose of Dexmedetomidine for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia With or Without Fentanyl by Age Groups: Randomized Comparative Study
Recently many studies reported that intraoperative dexmedetomidine administration undergoing spinal anesthesia give a satisfactory sedation in elderly patients and cause less respiratory depressions compared other sedatives(e.g.
- Trial name
- NCT01665586
- Testing
- dexmedetomidine
- Where
- South Korea
- Volunteers
- 82 people
- Sponsor
- Yonsei University
Bladder Cancer, Staging
Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale
Bladder cancer is the most common malignant tumor of the urinary system. The presence or absence of muscle invasion in early bladder cancer is an independent prognostic factor.
- Conditions
- Bladder Cancer, Staging, Deep Learning, Neoadjuvant Chemotherapy
- Trial name
- MICS-BC (NCT07051083)
- Testing
- Risk Stratification
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.